Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial

PURPOSE: In the phase III METEOR trial (ClinicalTrials.gov identifier: NCT01865747), 658 previously treated patients with advanced renal cell carcinoma were randomly assigned 1:1 to receive cabozantinib or everolimus. The cabozantinib arm had improved progression-free survival, overall survival, and...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Cella, David, Escudier, Bernard, Tannir, Nizar M., Powles, Thomas, Donskov, Frede, Peltola, Katriina, Schmidinger, Manuela, Heng, Daniel Y.C., Mainwaring, Paul N., Hammers, Hans J., Lee, Jae Lyun, Roth, Bruce J., Marteau, Florence, Williams, Paul, Baer, John, Mangeshkar, Milan, Scheffold, Christian, Hutson, Thomas E., Pal, Sumanta, Motzer, Robert J., Choueiri, Toni K.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2018
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6804841/
https://ncbi.nlm.nih.gov/pubmed/29377755
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.75.2170
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados